nach oben

Erschienen in:

05.06.2020 | BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Sacral Neuromodulation in the Management of Bladder Pain Syndrome/Interstitial Cystitis

verfasst von: David Hernández-Hernández, Bárbara Padilla-Fernández, Miguel Ángel Navarro-Galmés, Stephany Hess-Medler, María Milagros Castro-Romera, David Manuel Castro-Díaz

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, the current literature available about sacral neuromodulation (SNM) in the management of bladder pain syndrome/interstitial cystitis (BPS/IC) will be addressed.

Recent Findings

SNM has emerged in recent years as a minimally invasive option of management for refractory BPS/IC patients that otherwise should undergo reconstructive procedures. Although not approved by the FDA for this specific group of patients, the available data show a favourable response in both objective and subjective variables with a long-lasting effect. The implantation rate after the test phase is greater with the insertion of the quadripolar tined lead than with the monopolar percutaneous nerve evaluation. Most complications can be managed with reprogramming. The reintervention rate is still high, although it decreases when excluding surgeries for battery exchange.

Summary

Sacral neuromodulation should be considered in the treatment algorithm of patients with BPS/IC, as suggested in international guidelines. It provides symptomatic relief in a significant proportion of patients, being a fully reversible procedure with a very favourable complications’ profile. Reintervention or explantation risk factors have not been consistently established.

van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7. https://doi.org/10.1016/j.eururo.2007.09.019.CrossRefPubMed

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. https://doi.org/10.1002/nau.10052.CrossRefPubMed

Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145(4):732–5. https://doi.org/10.1016/s0022-5347(17)38437-9.CrossRefPubMed

Hauser PJ, Dozmorov MG, Bane BL, Slobodov G, Culkin DJ, Hurst RE. Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis. J Urol. 2008;179(2):764–9. https://doi.org/10.1016/j.juro.2007.09.022.CrossRefPubMed

Keay S, Kaczmarek P, Zhang CO, Koch K, Szekely Z, Barchi JJ Jr, et al. Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor. Chem Biol Drug Des. 2011;77(6):421–30. https://doi.org/10.1111/j.1747-0285.2011.01108.x.CrossRefPubMedPubMedCentral

Dundore PA, Schwartz AM, Semerjian H. Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. J Urol. 1996;155(3):885–7.CrossRefPubMed

Peeker R, Enerback L, Fall M, Aldenborg F. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J Urol. 2000;163(3):1009–15.CrossRefPubMed

Silk MR. Bladder antibodies in interstitial cystitis. J Urol. 1970;103(3):307–9. https://doi.org/10.1016/s0022-5347(17)61948-7.CrossRefPubMed

Mattila J, Linder E. Immunoglobulin deposits in bladder epithelium and vessels in interstitial cystitis: possible relationship to circulating anti-intermediate filament autoantibodies. Clin Immunol Immunopathol. 1984;32(1):81–9. https://doi.org/10.1016/0090-1229(84)90045-x.CrossRefPubMed

10.

Anderson JB, Parivar F, Lee G, Wallington TB, MacIver AG, Bradbrook RA, et al. The enigma of interstitial cystitis--an autoimmune disease? Br J Urol. 1989;63(1):58–63. https://doi.org/10.1111/j.1464-410x.1989.tb05124.x.CrossRefPubMed

11.

Ochs RL. Autoantibodies and interstitial cystitis. Clin Lab Med. 1997;17(3):571–9.CrossRefPubMed

12.

Peeker R, Atanasiu L, Logadottir Y. Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol. 2003;37(1):60–3. https://doi.org/10.1080/00365590310008721.CrossRefPubMed

13.

Breser ML, Salazar FC, Rivero VE, Motrich RD. Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome. Front Immunol. 2017;8:898. https://doi.org/10.3389/fimmu.2017.00898.CrossRefPubMedPubMedCentral

14.

Lynes WL, Sellers RG, Shortliffe LMD. The evidence for occult bacterial infections as a cause for interstitial cystitis. J Urol. 1989;141:268A.

15.

Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90. https://doi.org/10.1016/j.urology.2007.12.091.CrossRefPubMed

16.

Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol. 2012;12:205. https://doi.org/10.1186/1471-2180-12-205.CrossRefPubMedPubMedCentral

17.

Nickel JC, Stephens A, Landis JR, Mullins C, van Bokhoven A, Lucia MS, et al. Assessment of the lower urinary tract microbiota during symptom flare in women with urologic chronic pelvic pain syndrome: a MAPP network study. J Urol. 2016;195(2):356–62. https://doi.org/10.1016/j.juro.2015.09.075.CrossRefPubMed

18.

Qin C, Foreman RD. Viscerovisceral convergence of urinary bladder and colorectal inputs to lumbosacral spinal neurons in rats. Neuroreport. 2004;15(3):467–71. https://doi.org/10.1097/00001756-200403010-00017.CrossRefPubMed

19.

Malykhina AP, Qin C, Greenwood-van Meerveld B, Foreman RD, Lupu F, Akbarali HI. Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. Neurogastroenterol Motil. 2006;18(10):936–48. https://doi.org/10.1111/j.1365-2982.2006.00807.x.CrossRefPubMed

20.

Yoshikawa S, Kawamorita N, Oguchi T, Funahashi Y, Tyagi P, Chancellor MB, et al. Pelvic organ cross-sensitization to enhance bladder and urethral pain behaviors in rats with experimental colitis. Neuroscience. 2015;284:422–9. https://doi.org/10.1016/j.neuroscience.2014.08.064.CrossRefPubMed

21.

Grundy L, Erickson A, Caldwell A, Garcia-Caraballo S, Rychkov G, Harrington A, et al. Tetrodotoxin-sensitive voltage-gated sodium channels regulate bladder afferent responses to distension. Pain. 2018;159(12):2573–84. https://doi.org/10.1097/j.pain.0000000000001368.CrossRefPubMed

22.

Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology. 2007;69(4 Suppl):24–33. https://doi.org/10.1016/j.urology.2006.08.1108.CrossRefPubMed

23.

Engeler DS, Baranowski AP, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64(3):431–9. https://doi.org/10.1016/j.eururo.2013.04.035.CrossRefPubMed

24.

Oravisto KJ. Epidemiology of interstitial cystitis. Annales chirurgiae et gynaecologiae Fenniae. 1975;64(2):75–7.PubMed

25.

Leppilahti M, Sairanen J, Tammela TL, Aaltomaa S, Lehtoranta K, Auvinen A. Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J Urol. 2005;174(2):581–3. https://doi.org/10.1097/01.ju.0000165452.39125.98.CrossRefPubMed

26.

Held P, Hanno P, Wein A. Epidemiology of interstitial cystitis. In: Hanno P, Staskin D, Krane R, editors. Interstitial cystitis. New York: Springer-Verlag; 1990. p. 29–48.CrossRef

27.

Morales-Solchaga G, Zubiaur-Libano C, Peri-Cusi L, Adot-Zurbano JM, Arlandis-Guzman S, Franco-de Castro A, et al. Bladder pain syndrome: prevalence and routine clinical practice in women attending functional urology and urodynamics units in Spain. Actas Urol Esp. 2019;43(2):62–70. https://doi.org/10.1016/j.acuro.2018.06.004.CrossRefPubMed

28.

Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LM Jr, McKinlay JB. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol. 2007;177(4):1390–4. https://doi.org/10.1016/j.juro.2006.11.084.CrossRefPubMed

29.

Baskin L, Tanagho E. Pelvic pain without pelvic organs. J Urol. 1992;147(3):683–6.CrossRefPubMed

30.

Rössberger J, Fall M, Jonsson O, Peeker R. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007;70(4):638–42.CrossRefPubMed

31.

Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J Urol. 1998;159(5):1479–82. https://doi.org/10.1097/00005392-199805000-00018.CrossRefPubMed

32.

van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis. J Urol. 2002;167(2 Pt 1):603–7. https://doi.org/10.1097/00005392-200202000-00033.CrossRefPubMed

33.

Tahseen S. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature. Int Urogynecol J. 2018;29(8):1081–91. https://doi.org/10.1007/s00192-017-3546-6.CrossRefPubMed

34.

• Weissbart SJ, Bhavsar R, Rao H, Wein AJ, Detre JA, Arya LA, et al. Specific changes in brain activity during urgency in women with overactive bladder after successful sacral neuromodulation: a functional magnetic resonance imaging study. J Urol. 2018;200(2):382–8. https://doi.org/10.1016/j.juro.2018.03.129Functional MRI is changing the paradigm of the mechanism of action of neuromodulation. CrossRefPubMed

35.

• Gill BC, Pizarro-Berdichevsky J, Bhattacharyya PK, Brink TS, Marks BK, Quirouet A, et al. Real-time changes in brain activity during sacral neuromodulation for overactive bladder. J Urol. 2017;198(6):1379–85. https://doi.org/10.1016/j.juro.2017.06.074Functional MRI is changing the paradigm of the mechanism of action of neuromodulation. CrossRefPubMed

36.

Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–9. https://doi.org/10.1126/science.150.3699.971.CrossRefPubMed

37.

Birder LA, de Groat WC. Induction of c-fos expression in spinal neurons by nociceptive and nonnociceptive stimulation of LUT. Am J Phys. 1993;265(2 Pt 2):R326–33. https://doi.org/10.1152/ajpregu.1993.265.2.R326.CrossRef

38.

Ruch TC. Visceral sensation and referred pain. Fulton Howell’s Textbook of Physiology. 15th ed. Philadelphia, PA: Saunders; 1946. p. 385–401.

39.

Thon WF, Baskin LS, Jonas U, Tanagho EA, Schmidt RA. Neuromodulation of voiding dysfunction and pelvic pain. World J Urol. 1991;9(3):138–41. https://doi.org/10.1007/BF00202508.CrossRef

40.

Shaker H, Hassouna MM. Sacral root neuromodulation in the treatment of various voiding and storage problems. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):336–43. https://doi.org/10.1007/s001929970012.CrossRefPubMed

41.

Zermann DH, Weirich T, Wunderlich H, Reichelt O, Schubert J. Sacral nerve stimulation for pain relief in interstitial cystitis. Urol Int. 2000;65(2):120–1. https://doi.org/10.1159/000064852.CrossRefPubMed

42.

Chai TC, Zhang C, Warren JW, Keay S. Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis. Urology. 2000;55(5):643–6. https://doi.org/10.1016/s0090-4295(00)00476-3.CrossRefPubMed

43.

Maher CF, Carey MP, Dwyer PL, Schluter PL. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol. 2001;165(3):884–6.CrossRefPubMed

44.

Siegel S, Paszkiewicz E, Kirkpatrick C, Hinkel B, Oleson K. Sacral nerve stimulation in patients with chronic intractable pelvic pain. J Urol. 2001;166(5):1742–5.CrossRefPubMed

45.

Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol. 2003;169(4):1369–73. https://doi.org/10.1097/01.ju.0000053863.96967.5a.CrossRefPubMed

46.

Peters KM, Carey JM, Konstandt DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(4):223–8; discussion 8. https://doi.org/10.1007/s00192-003-1070-3.CrossRefPubMed

47.

Powell CR, Kreder KJ. Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol. 2010;183(1):173–6. https://doi.org/10.1016/j.juro.2009.08.142.CrossRefPubMed

48.

Whitmore KE, Payne CK, Diokno AC, Lukban JC. Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(5):305–8; discussion 8-9. https://doi.org/10.1007/s00192-003-1080-1.CrossRefPubMed

49.

Kessler TM, Buchser E, Meyer S, Engeler DS, Al-Khodairy AW, Bersch U, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol. 2007;51(5):1357–63. https://doi.org/10.1016/j.eururo.2006.11.011.CrossRefPubMed

50.

Marinkovic SP, Gillen LM, Marinkovic CM. Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J. 2011;22(4):407–12. https://doi.org/10.1007/s00192-010-1235-9.CrossRefPubMed

51.

Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int. 2011;107(8):1258–64. https://doi.org/10.1111/j.1464-410X.2010.09697.x.CrossRefPubMed

52.

Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–5. https://doi.org/10.1002/nau.21037.CrossRefPubMed

53.

Shih C, Miller JL, Fialkow M, Vicars BG, Yang CC. Reoperation after sacral neuromodulation therapy: a single-institution experience. Female pelvic medicine & reconstructive surgery. 2013;19(3):175–8. https://doi.org/10.1097/SPV.0b013e31828ab3c9.CrossRef

54.

Peters KM, Killinger KA, Gilleran JP, Bartley J, Wolfert C, Boura JA. Predictors of reoperation after sacral neuromodulation: a single institution evaluation of over 400 patients. Neurourol Urodyn. 2017;36(2):354–9. https://doi.org/10.1002/nau.22929.CrossRefPubMed

55.

Donon L, Robert G, Ballanger P. Sacral neuromodulation: results of a monocentric study of 93 patients. Prog Urol. 2014;24(17):1120–31. https://doi.org/10.1016/j.purol.2014.09.037.CrossRefPubMed

56.

Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113(5):789–94. https://doi.org/10.1111/bju.12571.CrossRefPubMed

57.

Elhilali MM, Khaled SM, Kashiwabara T, Elzayat E, Corcos J. Sacral neuromodulation: long-term experience of one center. Urology. 2005;65(6):1114–7. https://doi.org/10.1016/j.urology.2004.12.016.CrossRefPubMed

58.

Peters KM, Konstandt D. Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis. BJU Int. 2004;93(6):777–9. https://doi.org/10.1111/j.1464-410X.2003.04745.x.CrossRefPubMed

59.

Peters KM, Jayabalan N, Bui D, Killinger K, Chancellor M, Tyagi P. Effect of sacral neuromodulation on outcome measures and urine chemokines in interstitial cystitis/painful bladder syndrome patients. LUTS: Lower Urinary Tract Symptoms. 2015;7(2):77–83. https://doi.org/10.1111/luts.12054.CrossRefPubMed

60.

•• Mahran A, Baaklini G, Hassani D, Abolella HA, Safwat AS, Neudecker M, et al. Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature. Int Urogynecol J. 2019;30(7):1023–35. https://doi.org/10.1007/s00192-019-03898-wThe most recent systematic review on the topic. CrossRefPubMed

61.

Wang J, Chen Y, Chen J, Zhang G, Wu P. Sacral neuromodulation for refractory bladder pain syndrome/interstitial cystitis: a global systematic review and meta-analysis. Sci Rep. 2017;7(1):11031. https://doi.org/10.1038/s41598-017-11062-x.CrossRefPubMedPubMedCentral

62.

Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185(3):981–6. https://doi.org/10.1016/j.juro.2010.10.054.CrossRefPubMed

63.

Zabihi N, Mourtzinos A, Maher MG, Raz S, Rodriguez LV. Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):553–7. https://doi.org/10.1007/s00192-007-0466-x.CrossRefPubMed

64.

Istek A, Gungor Ugurlucan F, Yasa C, Gokyildiz S, Yalcin O. Randomized trial of long-term effects of percutaneous tibial nerve stimulation on chronic pelvic pain. Arch Gynecol Obstet. 2014;290(2):291–8. https://doi.org/10.1007/s00404-014-3190-z.CrossRefPubMed

65.

Ragab MM, Tawfik AM, Abo El-enen M, Elnady M, El-Gamal OM, El-Kordy M, et al. Evaluation of percutaneous tibial nerve stimulation for treatment of refractory painful bladder syndrome. Urology. 2015;86(4):707–11. https://doi.org/10.1016/j.urology.2015.06.041.CrossRefPubMed

66.

Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29(7):1267–71. https://doi.org/10.1002/nau.20823.CrossRefPubMed

67.

Possover M. The laparoscopic implantation of neuroprothesis to the sacral plexus for therapy of neurogenic bladder dysfunctions after failure of percutaneous sacral nerve stimulation. Neuromodulation. 2010;13(2):141–4. https://doi.org/10.1111/j.1525-1403.2009.00230.x.CrossRefPubMed

68.

Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018;122(5):729–43. https://doi.org/10.1111/bju.14399.CrossRefPubMed

69.

•• Hanno P, Cervigni M, Dinis P, Lin A, Nickel JC, Nordling J et al. Bladder pain syndrome. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th ed.: International Consultation on Incontinence 2017. The ICI document (ICS guideline) gives evidence-based recommendations on the topic.

70.

Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP et al. Diagnosis and treatment interstitial cystitis/bladder pain syndrome (2014). American Urological Association Education and Research; 2014.

71.

Engeler D, Baranowski AP, Berghmans B, Borovicka J, Cottrell AM, Elneil PS, et al. EAU guidelines on chronic pelvic pain in: EAU guidelines. The Netherlands: European Association of Urology; 2019. https://uroweb.org/guideline/chronic-pelvic-pain/

Titel: Sacral Neuromodulation in the Management of Bladder Pain Syndrome/Interstitial Cystitis
verfasst von: David Hernández-Hernández
Bárbara Padilla-Fernández
Miguel Ángel Navarro-Galmés
Stephany Hess-Medler
María Milagros Castro-Romera
David Manuel Castro-Díaz
Publikationsdatum: 05.06.2020
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 2/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-020-00579-z

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Is Urinary Retention Following Extravesical Ureteral Reimplantation Still a Concern?

Vaginal Mesh Survivorship

Valve Bladder Syndrome Associated with Posterior Urethral Valves: Natural History, Work-up, and Management

Predicting Upper Urinary Tract Risk in the Neurogenic Bladder Patient